ATX-201
- Generic Name
- ATX-201
- Drug Type
- Small Molecule
Overview
ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their expected primary and exploratory objectives.
Background
ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their expected primary and exploratory objectives.
Indication
Investigated for use/treatment in actinic keratosis.
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.